BOSTON , Feb. 28, 2025 /PRNewswire/ - John Hancock Premium Dividend Fund (NYSE: PDT) (the "Fund"), a closed-end fund managed by John Hancock Investment Management LLC and subadvised by Manulife Investment Management (US) LLC, announced today sources of its monthly distribution of $0.0825 per share paid to all shareholders of record as of February 13, 2025, pursuant to the Fund's managed distribution plan. This press release is issued as required by an exemptive order granted to the Fund by the U.S. Securities and Exchange Commission.
BOSTON , Jan. 31, 2025 /PRNewswire/ - John Hancock Premium Dividend Fund (NYSE: PDT) (the "Fund"), a closed-end fund managed by John Hancock Investment Management LLC and subadvised by Manulife Investment Management (US) LLC, announced today sources of its monthly distribution of $0.0825 per share paid to all shareholders of record as of January 13, 2025, pursuant to the Fund's managed distribution plan. This press release is issued as required by an exemptive order granted to the Fund by the U.S. Securities and Exchange Commission.
The John Hancock Premium Dividend Fund offers a 7.78% yield, higher than domestic broad-market equity indices and preferred stocks, making it attractive for income-focused investors. The fund's yield is lower than some of its peers, but it also includes equities in its portfolio. The fund's strategy of investing in both common equities and preferred stocks provides potential for capital gains, which is nice should inflation continue to accelerate.
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC (ALA-BCC-CT013) was met with the last patient completing the 1 year follow-up visit in December of 2024.
BOSTON , Dec. 31, 2024 /PRNewswire/ - John Hancock Premium Dividend Fund (NYSE: PDT) (the "Fund"), a closed-end fund managed by John Hancock Investment Management LLC and subadvised by Manulife Investment Management (US) LLC, announced today sources of its monthly distribution of $0.0825 per share paid to all shareholders of record as of December 12, 2024, pursuant to the Fund's managed distribution plan. This press release is issued as required by an exemptive order granted to the Fund by the U.S. Securities and Exchange Commission.
BOSTON , Nov. 29, 2024 /PRNewswire/ - John Hancock Premium Dividend Fund (NYSE: PDT) (the "Fund"), a closed-end fund managed by John Hancock Investment Management LLC and subadvised by Manulife Investment Management (US) LLC, announced today sources of its monthly distribution of $0.0825 per share paid to all shareholders of record as of November 12, 2024, pursuant to the Fund's managed distribution plan. This press release is issued as required by an exemptive order granted to the Fund by the U.S. Securities and Exchange Commission.
VANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three and nine months ended September 30, 2024. All dollar amounts are in US dollars (US$).
BOSTON , Oct. 31, 2024 /PRNewswire/ - John Hancock Premium Dividend Fund (NYSE: PDT) (the "Fund"), a closed-end fund managed by John Hancock Investment Management LLC and subadvised by Manulife Investment Management (US) LLC, announced today sources of its monthly distribution of $0.0825 per share paid to all shareholders of record as of October 11, 2024, pursuant to the Fund's managed distribution plan. This press release is issued as required by an exemptive order granted to the Fund by the U.S. Securities and Exchange Commission.
WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announced today that the database for the treatment phase of study ALA-BCC-CT013 has been locked.
BOSTON , Oct. 1, 2024 /PRNewswire/ - The John Hancock closed-end funds listed below declared their monthly distributions today as follows: Declaration Date: October 1, 2024 Ex Date: October 11, 2024 Record Date: October 11, 2024 Payment Date: October 31, 2024 Ticker Fund Name Distribution Per Share Change From Previous Distribution Market Price as of 9/30/2024 Annualized Current Distribution Rate at Market HPI Preferred Income Fund $0.1235 - $18.95 7.82 % HPF Preferred Income Fund II $0.1235 - $18.65 7.95 % HPS Preferred Income Fund III $0.1100 - $17.24 7.66 % PDT Premium Dividend Fund $0.0825 - $13.22 7.49 % HTD Tax-Advantaged Dividend Income Fund $0.1380 - $23.22 7.13 % John Hancock Premium Dividend Fund Premium Dividend Fund (the "Fund") declared its monthly distribution pursuant to the Fund's managed distribution plan (the "PDT Plan"). Under the PDT Plan, the Fund makes monthly distributions of an amount equal to $0.0825 per share.